Modern pharmacotherapy of polycystic ovary syndrome
Shabatukova E.V., Shcherban D.A., Kudratova E.A., Skvortsova A.A., Zhukova O.V.
The article analyzes modern pharmacotherapeutic approaches to the treatment of polycystic ovary syndrome (PCOS), which is one of the most common endocrine disorders among reproductive-aged women. The main statistical indicators of PCOS prevalence are given and the clinical manifestations of this disease are described. The application of combined oral contraceptives, antiandrogenic medications, and insulin sensitizers as first-line pharmacotherapeutic correction methods has been examined. The results of clinical studies confirming the effectiveness of these drugs are summarized and the need for further research to optimize therapy regimens is emphasized. The paper investigates the use of antiandrogens such as spironolactone and cyproterone acetate for correcting androgen-dependent manifestations of PCOS. Additionally, new approaches to PCOS therapy using glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have shown effectiveness in lowering glucose levels, are analyzed. The article emphasizes the significance of additional clinical studies to assess the long-term effects of combined therapy and improve treatment results for patients with PCOS. One of the main goals is to improve insulin sensitivity by using drugs like metformin, which helps to normalize metabolic parameters. Special attention is paid to the role of antiandrogens in correcting the symptoms of hyperandrogenism, namely hirsutism and acne; side effects and individual characteristics of patients are considered as well.
Conclusion: It is necessary to use a differentiated approach to treatment which can depend on the PCOS phenotype and the presence of concomitant metabolic disorders.
Authors’ contributions: Shabatukova E.V., Shcherban D.A. – developing the concept and design of the study; Kudratova E.A., Skvortsova A.A., Zhukova O.V. – collecting and processing the material; Zhukova O.V., Shabatukova E.V. – statistical data processing; Shcherban D.A., Kudratova E.A., Skvortsova A.A. – writing the text; Shabatukova E.V., Shcherban D.A., Zhukova O.V. – editing the article. The authors contributed equally to writing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interest.
Funding: The study was conducted without sponsorship.
For citation: Shabatukova E.V., Shcherban D.A., Kudratova E.A., Skvortsova A.A., Zhukova O.V.
Modern pharmacotherapy of polycystic ovary syndrome.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2025; (7): 153-160 (in Russian)
https://dx.doi.org/10.18565/aig.2025.83
Keywords
polycystic ovary syndrome
hormonal therapy
oral contraceptives
antiandrogens
metformin
insulin resistance
reproductive function
metabolic disorders
References
- Адамян Л.В., Андреева Е.Н., Абсатарова Ю.С., Григорян О.Р., Дедов И.И., Мельниченко Г.А., Сутурина Л.В., Филиппов О.С., Шереметьева Е.В., Чернуха Г.Е., Ярмолинская М.И. Клинические рекомендации «Синдром поликистозных яичников». Проблемы эндокринологии. 2022; 68(2): 112-27. [Adamyan L.V., Andreeva E.N., Absatarova Yu.S., Grigoryan O.R., Dedov I.I., Melnichenko G.A., Suturina L.V., Filippov O.S., Sheremetyeva E.V., Chernukha G.E., Yarmolinskaya M.I. Clinical guidelines «Polycystic Ovary Syndrome». Problems of Endocrinology. 2022; 68(2): 112-27 (in Russian)]. https://dx.doi.org/10.14341/probl12874
- Беглова А.Ю., Елгина С.И., Гордеева Л.А. Полиморфизм генов CYP11a1, CYP17, CYP19 у женщин репродуктивного возраста с синдромом поликистозных яичников. Акушерство и гинекология. 2019; 12: 148-53. [Beglova A.Yu., Elgina S.I., Gordeeva L.A. Polymorphism of the CYP11A1, CYP17A1, and CYP19A1 genes in reproductive-aged women with polycystic ovary syndrome. Obstetrics and Gynecology. 2019; (12): 148-53 (in Russian)]. https://dx.doi.org/10.18565/aig.2019.12.148-153
- Всемирная организация здравоохранения. Информационный бюллетень. Синдром поликистозных яичников. [World Health Organization. Fact sheets. Polycystic ovary syndrome (in Russian)]. https://www.who.int/ru/news-room/fact-sheets/detail/polycystic-ovary-syndrome
- Sadeghi H.M., Adeli I., Calina D., Docea A.O., Mousavi T., Daniali M. et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int. J. Mol. Sci. 2022; 23(2): 583. https://dx.doi.org/10.3390/ijms23020583
- Гасиева Д.М., Шереметьева Е.В., Калашникова М.Ф., Дзгоева Ф.Х., Алборова Е.Т. Синдром поликистозных яичников: новые и перспективные варианты лечения. Проблемы эндокринологии. 2024; 70(4): 103-13. [Gasieva D.M., Sheremetyeva E.V., Kalashnikova M.F., Dzgoeva F.Kh., Alborova E.T. Polycystic ovary syndrome: new and promising treatment methods. Problems of Endocrinology. 2024; 70(4): 103-13 (in Russian)]. https://dx.doi.org/10.14341/probl13400
- Huddleston H.G., Dokras A. Diagnosis and treatment of polycystic ovary syndrome. JAMA. 2022; 327(3): 274-75. https://dx.doi.org/10.1001/jama.2021.23769
- Oguz S.H., Yildiz B.O. An update on contraception in polycystic ovary syndrome. Endocrinol. Metab. (Seoul). 2021; 36(2): 296-311. https://dx.doi.org/10.3803/EnM.2021.958
- Красильникова А.К., Малышкина Д.А. Преимущества фолатсодержащих комбинированных оральных контрацептивов при лечении синдрома поликистозных яичников. Акушерство и гинекология. 2019; 9: 182-6. [Krasilnikova A.K., Malyshkina D.A. Advantages of folate-containing combined oral contraceptives in the treatment of polycystic ovary syndrome. Obstetrics and Gynecology. 2019; (9): 182-6 (in Russian)]. https://dx.doi.org/10.18565/aig.2019.9.182-186
- Cooper D.B., Patel P. Oral contraceptive pills. Treasure Island : StatPearls, 2024.
- Лазарева Л.М., Шарифулин Э.М., Беленькая Л.В., Сутурина Л.В. СПКЯ в репродуктивном возрасте: фенотипическое разнообразие и диагностические подходы (обзор литературы). Доктор.Ру. 2020; 19(6): 50-6. [Lazareva L.M., Sharifulin E.M., Belenkaya L.V., Suturina L.V. SPKY in reproductive age: phenotypic diversity and diagnostic approaches (literature review). Doctor.Ru. 2020; 19(6): 50-6 (in Russian)]. https://dx.doi.org/10.31550/1727-2378-2020-19-6-50-56
- Forslund M., Melin J., Alesi S., Piltonen T., Romualdi D., Tay C.T. et al. Different kinds of oral contraceptive pills in polycystic ovary syndrome: a systematic review and meta-analysis. Eur. J. Endocrinol. 2023; 189(1): 1-16. https://dx.doi.org/10.1093/ejendo/lvad082
- Manique M.E.S., Ferreira A.M.A. Polycystic ovary syndrome in adolescence: challenges in diagnosis and management. Rev. Bras. Ginecol. Obstet. 2022; 44(4): 425-33. https://dx.doi.org/10.1055/s-0042-1742292
- Sarfraz N., Akram H., Abbas A., Shaheen S., Zafar R., Yaqoob E. Efficacy of cyproterone acetate and drosperinone containing cocps in treatment of hirsutism in patients with PCOS. JRMC. 2023; 27(3). https://dx.doi.org/10.37939/jrmc.v27i3.2283
- Sha Y., Zhu J., Shen F. A meta-analysis of efficacy on dexamethasone and clomiphene in the treatment of polycystic ovary syndrome patients. BMC Womens Health. 2024; 24(1): 298. https://dx.doi.org/10.1186/s12905-024-03141-9
- Shirin S., Murray F., Goshtasebi A., Kalidasan D., Prior J.C. Cyclic progesterone therapy in androgenic polycystic ovary syndrome (PCOS)-A 6-month pilot study of a single woman's experience changes. Medicina (Kaunas). 2021; 57(10): 1024. https://dx.doi.org/10.3390/medicina57101024
- Baracat M.C.P., Baracat E.C., Simões R.S., Simões M.J., Maciel G.A.R., Azziz R. et al. Hormonal and metabolic factors influence the action of progesterone on the endometrium of women with polycystic ovary syndrome. Diagnostics (Basel). 2023; 13(3): 382. https://dx.doi.org/10.3390/diagnostics13030382
- Kamenov Z., Gateva A. Inositols in PCOS. Molecules. 2020; 25(23): 5566. https://dx.doi.org/10.3390/molecules25235566
- Xing C., Li C., He B. Insulin sensitizers for improving the endocrine and metabolic profile in overweight women with PCOS. J. Clin. Endocrinol. Metab. 2020; 105(9): 2950-63. https://dx.doi.org/10.1210/clinem/dgaa337
- Rashid R., Mir S.A., Kareem O., Ali T., Ara R., Malik A. et al. Polycystic ovarian syndrome – current pharmacotherapy and clinical implications. Taiwan. J. of Obstet. Gynecol. 2022; 61(1): 40-50. https://dx.doi.org/10.1016/j.tjog.2021.11.009
- Nylander M., Frøssing S., Kistorp C., Faber J., Skouby S.O. Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential. Endocr. Connect. 2017; 6(2): 89-99. https://dx.doi.org/10.1530/EC-16-0113
- Tao X., Cai L., Chen L., Ge S., Deng X. Effects of metformin and exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats. J. Ovarian Res. 2019; 12(1): 86. https://dx.doi.org/10.1186/s13048-019-0555-8
- Ferjan S., Janez A., Jensterle M. DPP4 inhibitor sitagliptin as a potential treatment option in metformin-intolerant obese women with polycystic ovary syndrome: a pilot randomized study. Endocr. Pract. 2018; 24(1): 69-77. https://dx.doi.org/10.4158/EP-2017-0027
- Devin J.K., Nian H., Celedonio J.E., Wright P., Brown N.J. Sitagliptin decreases visceral fat and blood glucose in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 2020; 105(1): 136-51. https://dx.doi.org/10.1210/clinem/dgz028
- Javed Z., Papageorgiou M., Deshmukh H., Rigby A.S., Qamar U., Abbas J. et al. Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study. Clin. Endocrinol. (Oxf.). 2019; 90(6): 805-13. https://dx.doi.org/10.1111/cen.13968
Received 24.03.2025
Accepted 16.06.2025
About the Authors
Ekaterina V. Shabatukova, 6th year student, Faculty of Medicine, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia,117513, Russia, Moscow, Ostrovityanova str., 1, build. 6, +7(977)142-28-56, ka.shabbat@rambler.ru, https://orcid.org/0009-0009-8720-7971
Daria A. Shcherban, 6th year student, Faculty of Medicine, Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia,
660022, Russia, Krasnoyarsk, Partizan Zheleznyak str., 1, +7(983)362-35-16, darya_scherban@mail.ru, https://orcid.org/0009-0004-8911-5249
Ekaterina A. Kudratova, 6th year student, Faculty of Medicine, Tyumen State Medical University, Ministry of Health of Russia, 625023, Russia, Tyumen region, Tyumen, Odesskaya str., 54, +7(922)002-65-10, kate.kudratova@yandex.ru, https://orcid.org/0009-0007-4283-2840
Anastasiia A. Skvortsova, 6th year student, Faculty of Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia,
119048, Russia, Moscow, Trubetskaya str., 8, build. 2, +7(926)529-71-52, nmoiseecheva@mail.ru, https://orcid.org/0009-0000-4334-4709
Oksana V. Zhukova, 6th year student, Faculty of Medicine, N.N. Burdenko Voronezh State Medical University, Ministry of Health of Russia,
394036, Russia, Voronezh, Studencheskaya str., 10, +7(996)624-12-95, Oksana515@yandex.ru, https://orcid.org/0009-0001-8331-6873
Corresponding author: Ekaterina V. Shabatukova, ka.shabbat@rambler.ru
Similar Articles
